|
Company:
|
CYTODYN INC. (CYDY)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
3/2/2023
|
|
CIK:
|
0001175680
|
|
Address:
|
1111 MAIN STREET, SUITE 660
|
|
City, State, Zip:
|
VANCOUVER, Washington 98660
|
|
Telephone:
|
360-980-8524
|
|
Fiscal Year:
|
05/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$0.27
|
Change:
-0.01 (-3.48%)
|
Trade Time:
Jun 07
|
Market Cap:
$245.47M
|
|
|
|
|
|
|
Description of Business
|
|
CytoDyn Inc. (together with its wholly owned subsidiaries, the "Company", also
referred to as "CytoDyn", "we," "our," or "us" in this Form 10-K) was originally
incorporated under the laws of Colorado on May 2, 2002, under the name RexRay
Corporation and, effective August 27, 2015, reincorporated under the laws of
Delaware. The Company is a clinical-stage biotechnology company focused on the
clinical development of innovative treatments for multiple therapeutic
indications based on its product candidate, leronlimab (also referred to as PRO
140 in this Form 10-K), a novel humanized monoclonal antibody targeting the CCR5
receptor. The pre-clinical and early clinical development of PRO 140 was led by
Progenics Pharmaceuticals, Inc. ("Progenics") through 2011. The Company acquired
the asset from Progenics in October 2012; refer to Part II, Item 8, Note 10,
Commitments and Contingencies - PRO 140 Acquisition and Licensing Arrangements
of this Form 10-K for additional information.
|
|
|
|